Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Star Bulk Carriers Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Star Bulk Carriers Corp trades at $26.3 (market cap $2.92B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 3.93% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SBLK | |
|---|---|---|
Market Cap | $4.49B | $2.92B |
Sector | Health | Industrials |
52-Week High | $28.06 | $28.21 |
52-Week Low | $20.06 | $16.79 |
Enterprise Value | $3.69B | $3.62B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Star Bulk Carriers (SBLK) trades at $26.12, up 3.86% with bullish technical signals and strong earnings momentum after beating Q1 2026 estimates. The company shows solid fundamentals with 13.01% net income margin and positive cash flow, supported by a new dividend policy returning 100% of free cash flow. Analyst consensus is strongly bullish with 14 buy ratings.
SBLK presents a compelling investment case with earnings growth acceleration and shareholder-friendly capital allocation. Key risks include dry bulk market volatility and oil price sensitivity, but strong institutional support and technical momentum suggest continued upside potential for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
